AIM IMMUNOTECH INC. (AIM) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $480.00K; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $480.00K | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $480.00K |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 4.99M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 480.00K USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $300.00K |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $480.00K | (m) | (m) | (m) | $4.99M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.22M | (m) | (m) | (m) | $6.46M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $1.63M | (m) | (m) | (m) | $15.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.25M | (m) | (m) | (m) | $11.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.30M | (m) | (m) | (m) | $10.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $6.94M | (m) | (m) | (m) | $10.11M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.38M | (m) | (m) | (m) | $9.93M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.26M | (m) | (m) | (m) | $10.68M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $5.46M | (m) | (m) | (m) | $9.61M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $6.57M | (m) | (m) | (m) | $11.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.44M | (m) | (m) | (m) | $9.15M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $963.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $377.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $957.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $712.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $378.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $198.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $369.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $451.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $189.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $383.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $205.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $255.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $165.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $472.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $620.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $672.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $768.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $680.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $791.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $689.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $850.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $741.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $460.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $972.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $927.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $887.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $1.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $1.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $1.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $2.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.08M | (m) | (m) | (m) | $4.44M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $2.45M | (m) | (m) | (m) | $4.27M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.47M | (m) | (m) | (m) | $4.18M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.22M | (m) | (m) | (m) | $3.02M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.27M | (m) | (m) | (m) | $2.57M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.72M | (m) | (m) | (m) | $10.73M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $967.00K | (m) | (m) | (m) | $10.00M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $1.67M | (m) | (m) | (m) | $10.28M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $2.16M | (m) | (m) | (m) | $13.00M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $2.34M | (m) | (m) | (m) | $11.97M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $1.80M | (m) | (m) | (m) | $7.58M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.46M | (m) | (m) | (m) | $6.60M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $1.68M | (m) | (m) | (m) | $5.55M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $1.58M | (m) | (m) | (m) | $4.96M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $1.12M | (m) | (m) | (m) | $3.93M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.33M | (m) | (m) | (m) | $5.73M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |